Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma.
Zabransky DJ, Kartalia E, Lee JW, Leatherman JM, Charmsaz S, Young SE, Chhabra Y, Franch-Expósito S, Kang M, Maru S, Rastkari N, Davis M, Dalton WB, Oshima K, Baretti M, Azad NS, Jaffee EM, Yarchoan M. Zabransky DJ, et al. Among authors: baretti m. Hepatology. 2024 Dec 3. doi: 10.1097/HEP.0000000000001185. Online ahead of print. Hepatology. 2024. PMID: 39626209
Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial.
Baretti M, Danilova L, Durham JN, Betts CB, Cope L, Sidiropoulos DN, Tandurella JA, Charmsaz S, Gross N, Hernandez A, Ho WJ, Thoburn C, Walker R, Leatherman J, Mitchell S, Christmas B, Saeed A, Gaykalova DA, Yegnasubramanian S, Fertig EJ, Coussens LM, Yarchoan M, Jaffee E, Azad NS. Baretti M, et al. Nat Commun. 2024 Nov 12;15(1):9801. doi: 10.1038/s41467-024-52528-7. Nat Commun. 2024. PMID: 39532835 Free PMC article. Clinical Trial.
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma.
Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, Lee JW, Sidiropoulos DN, Mitchell S, Munjal K, Howe K, Bendinelli KJ, Kartalia E, Qi H, Mo G, Montagne J, Leatherman JM, Lopez-Vidal TY, Zhu Q, Huff AL, Yuan X, Hernandez A, Coyne EM, Zaidi N, Zabransky DJ, Engle LL, Ogurtsova A, Baretti M, Laheru D, Durham JN, Wang H, Sunshine JC, Johnston RJ, Deutsch JS, Taube JM, Anders RA, Jaffee EM, Fertig EJ, Yarchoan M. Shu DH, et al. Among authors: baretti m. Nat Immunol. 2024 Nov;25(11):2110-2123. doi: 10.1038/s41590-024-01992-w. Epub 2024 Oct 25. Nat Immunol. 2024. PMID: 39455893
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.
D'Alessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, Slater S, Fulgenzi CAM, Celsa C, Manfredi GF, Pai M, Goldin RD, Ward SC, Fiel MI, Shu DH, Su YY, Cortellini A, Baretti M, Anders R, Yarchoan M, Hsu C, Marron TU, Pinato DJ. D'Alessio A, et al. Among authors: baretti m. Lancet Oncol. 2024 Nov;25(11):1465-1475. doi: 10.1016/S1470-2045(24)00457-1. Epub 2024 Oct 19. Lancet Oncol. 2024. PMID: 39437804 Free article.
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
Kao CJ, Charmsaz S, Alden SL, Brancati M, Li HL, Balaji A, Munjal K, Howe K, Mitchell S, Leatherman J, Griffin E, Nakazawa M, Tsai HL, Danilova L, Thoburn C, Gizzi J, Gross NE, Hernandez A, Coyne EM, Shin SM, Babu JS, Apostol GW, Durham J, Christmas BJ, Konig MF, Lipson EJ, Naidoo J, Cappelli LC, Pabani A, Ged Y, Baretti M, Brahmer J, Hoffman-Censits J, Seiwert TY, Garonce-Hediger R, Guha A, Bansal S, Tang L, Jaffee EM, Chandler GS, Mohindra R, Ho WJ, Yarchoan M. Kao CJ, et al. Among authors: baretti m. J Clin Invest. 2024 Aug 29;134(20):e176567. doi: 10.1172/JCI176567. J Clin Invest. 2024. PMID: 39403935 Free PMC article. Clinical Trial.
Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC.
Nakazawa M, Fang M, Vong T, Zorzi J, Griffith P, Anders RA, Oshima K, Kim AK, Laurin J, Lafaro KJ, Shubert CR, Burns WR, He J, Burkhart RA, Philosophe B, Meyer J, Liddell RP, Georgiades C, Hong K, Ho WJ, Baretti M, Strauss AT, Yarchoan M. Nakazawa M, et al. Among authors: baretti m. Cancer Res Commun. 2024 Aug 1;4(8):2123-2132. doi: 10.1158/2767-9764.CRC-24-0151. Cancer Res Commun. 2024. PMID: 39142659 Free PMC article.
Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parameters.
Mohseni A, Baghdadi A, Madani SP, Shahbazian H, Mirza-Aghazadeh-Attari M, Borhani A, Afyouni S, Zandieh G, Baretti M, Kim AK, Yarchoan M, Kamel IR. Mohseni A, et al. Among authors: baretti m. Abdom Radiol (NY). 2024 Aug;49(8):2595-2605. doi: 10.1007/s00261-024-04257-0. Epub 2024 Mar 28. Abdom Radiol (NY). 2024. PMID: 38546828
Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade.
Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, Lee JW, Sidiropoulos DN, Mitchell S, Munjal K, Howe K, Bendinelli KJ, Qi H, Mo G, Montagne J, Leatherman JM, Lopez-Vidal TY, Zhu Q, Huff AL, Yuan X, Hernandez A, Coyne EM, Zaidi N, Zabransky DJ, Engle LL, Ogurtsova A, Baretti M, Laheru D, Durham JN, Wang H, Anders R, Jaffee EM, Fertig EJ, Yarchoan M. Shu DH, et al. Among authors: baretti m. bioRxiv [Preprint]. 2023 Oct 26:2023.10.16.562104. doi: 10.1101/2023.10.16.562104. bioRxiv. 2023. PMID: 37904980 Free PMC article. Preprint.
40 results